# EDGAR Filing Document

**Accession Number:** 0001412558
**File Stem:** 0001019056-26-000087
**Filing Date:** 2026-5
**Character Count:** 15780
**Document Hash:** 0d92bb85c4c344324595a2204df7269e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001019056-26-000087.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001019056-26-000087

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260501

**DATE AS OF CHANGE**: 20260501

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evotec SE
- **CENTRAL INDEX KEY:** 0001412558
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-84013
- **FILM NUMBER:** 26933617

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419
- **BUSINESS PHONE:** 49-40-560-810

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ESSENER BOGEN 7
- **CITY:** HAMBURG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 22419

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evotec AG
- **DATE OF NAME CHANGE:** 20070917
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAK Capital Fund LP
- **CENTRAL INDEX KEY:** 0001426156

**ORGANIZATION NAME:**
- **EIN:** 980416772
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 590 MADISON AVENUE
- **STREET 2:** 31ST FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-486-3211

**MAIL ADDRESS:**
- **STREET 1:** 590 MADISON AVENUE
- **STREET 2:** 31ST FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## Ex-1

**Exhibit 1**

**Transactions in the Securities of the Issuer During the Past 60 Days**

The following purchases were made on the open market, unless otherwise noted.

---

| | | |
|:---|:---|:---|
| **Date** | **Number of**<br> **Shares** | **Price Per** <br> **Share (EUR)** |
| 3/11/2026 | 250000 | 4.4192 |
| 3/12/2026 | 125000 | 4.3418 |
| 3/13/2026 | 250000 | 4.1544 |
| 3/16/2026 | 105699 | 4.1858 |
| 3/17/2026 | 33610 | 4.3043 |
| 3/18/2026 | 120000 | 4.3572 |
| 3/19/2026 | 140407 | 4.2906 |
| 3/20/2026 | 220000 | 4.3185 |
| 3/23/2026 | 36719 | 4.0685 |
| 3/25/2026 | 1233 | 4.3483 |
| 4/20/2026 | 32720 | 5.4385 |
| 4/21/2026 | 104702 | 5.6316 |
| 4/22/2026 | 40964 | 5.6383 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Evotec SE**

*(Name of Issuer)*

**Ordinary Shares, no par value per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**David N. Smith, Jr**<br>590 Madison Avenue<br>31st Floor<br>New York NY 10022<br>212-486-3211

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/29/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MAK Capital Fund LP** | Name of reporting person<br>**MAK Capital Fund LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D0** | Citizenship or place of organization<br>**D0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12681898.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12681898.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** For item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of May 1, 2026, as reported by the Issuer on its website.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MAK Capital One L.L.C.** | Name of reporting person<br>**MAK Capital One L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12681898.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12681898.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** For item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of May 1, 2026, as reported by the Issuer on its website.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Michael A. Kaufman** | Name of reporting person<br>**Michael A. Kaufman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**12681898.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**12681898.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | Aggregate amount beneficially owned by each reporting person<br>**12681898.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.1%** | Percent of class represented by amount in Row (11)<br>**7.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** For item 13:

The calculation is based upon 177,877,782 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of May 1, 2026, as reported by the Issuer on its website.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, no par value per share

**(b) Name of Issuer:**
Evotec SE

**(c) Address of Issuer's Principal Executive Offices:**
Essener Bogen 7, Hamburg, 2M, 22419

**Item 4. Purpose of Transaction**

SCHEDULE 13D A/2
Amendment 2

This Amendment 2 to the statement on Schedule 13D ("Amendment 2") to the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") by the MAK Capital Fund LP, a Bermuda limited partnership ("MAK Fund"), MAK Capital One L.L.C., a Delaware limited liability company ("MAK Capital"), as the investment manager of MAK Fund and Michael A. Kaufman, as Managing Member of MAK Capital (collectively with MAK Fund and MAK Capital, "MAK" and together MAK Fund and MAK Capital collectively the "Reporting Persons") on March 30, 2026 (the "Original Schedule 13D") and amendment number 1 thereto filed on April 6, 2026 ("Amendment 1" and together with this Amendment 2 and the Original Schedule 13D, "Schedule 13D") amends and supplements the Original Schedule 13D and Amendment 1 and relates to to the ordinary shares, no par value per share (the "Shares") of EVOTEC SE (the "Issuer") beneficially owned by the Reporting Persons. The principal executive offices of the Issuer are located at Essener Bogen 7, Hamburg, GERMANY , 22419.

Except as set forth herein in this Amendment 2, the Schedule 13D is unmodified.

In furtherance of the Purpose of Transaction, MAK Fund and Issuer signed a cooperation agreement on April 29, 2026.  Under the terms, described further in the press release by Issuer filed with the SEC as Exhibit 99.1 to Issuer's Current Report on Form 6-K on April 30, 2026, Issuer will nominate Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company's upcoming Annual General Meeting ("AGM") to be held on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, and a proposal to increase the size of the Supervisory Board from six to seven members.  Per the cooperation agreement MAK Fund has agreed to customary voting and cooperation commitments, including voting in favor of expanding the board to seven members and supporting the three candidates nominated by Issuer to the remaining three seats open for election. The summary above of the terms of the cooperation agreement is qualified in its entirety by reference to the press release, a copy of which is filed as Exhibit 99.1, to the Issuer's Current Report on Form 6-K filed on April 30, 2026 and is incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

The aggregate percentage of Shares reported owned by each person named herein is based upon 177,877,782 Shares (including Shares in the form of American Depositary Shares, each representing one-half of one Ordinary Share), outstanding as of May 01, 2026, as reported by the Issuer on its website.

As of the date hereof, MAK Fund beneficially owns directly 12,681,898 Shares, representing approximately 7.1% of the outstanding Shares.

MAK Capital, as the investment manager of MAK Fund, may be deemed to beneficially own the 12,681,898 Shares beneficially owned directly by MAK Fund, representing approximately 7.1% of the outstanding Shares. Mr. Kaufman, as the Managing Member of MAK Capital, may be deemed to beneficially own the 12,681,898 Shares beneficially owned directly by MAK Fund, representing approximately 7.1% of the outstanding Shares.

The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

**(b)**
Each of MAK Fund, MAK Capital and Mr. Kaufman may be deemed to share the power to vote and dispose of the Shares beneficially owned directly by MAK Fund.

**(c)**
The transactions in securities of the Issuer by the Reporting Persons during the past 60 days are set forth in Exhibit 1 and are incorporated herein by reference. All of such transactions were effected in the open market unless otherwise noted therein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended and supplemented by the addition of the following:

The information set forth in Item 4 of this Amendment 2 is incorporated by reference in its entirety into this Item 6.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MAK Capital Fund LP

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Managing Member

**Date:** 05/01/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MAK Capital One L.L.C.

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Managing Member

**Date:** 05/01/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Michael A. Kaufman

**Signature:** /s/ Michael A. Kaufman

**Name/Title:** Michael A. Kaufman

**Date:** 05/01/2026